Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
October 14 2024 - 12:45PM
UK Regulatory
Inventiva announces the availability of a prospectus in connection
with its financing through the issuance of ordinary shares and
pre-funded warrants
Daix (France), Long Island City (New
York, United States), October 14, 2024 – Inventiva
(Euronext Paris and Nasdaq: IVA) (“Inventiva” or
the “Company”), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of metabolic dysfunction-associated
steatohepatitis (“MASH”) and other diseases with
significant unmet medical needs, today announces that the
Autorité des marchés financiers (the
“AMF”) has approved a prospectus under no. 24-432,
on October 14, 2024, in connection with its financing through the
issuance of ordinary shares and pre-funded share warrants
The prospectus consists of:
- the universal registration document filed with the AMF on April
3, 2024 under number D. 24-0227
- the amendment to the 2023 universal registration document filed
on October 14, 2024 under number D. 24-0227-A01 incorporating by
reference the half-yearly financial report as of June 30, 2024
published on October14, 2024 on the Company's website;
- the securities note; and
- the Prospectus summary (included in the securities note).
These documents can be viewed on the Company's
website at www.inventivapharma.com, in the “Investors” section, and
on the AMF website at www.amf-france.org. Copies of the universal
registration document, as amended, are also available free of
charge, on request, from the Company's registered office at 50 Rue
de Dijon, 21121 Daix, France.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH and
other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937 |
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83 |
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
- Inventiva - PR - Prospectus - EN - 10 14 2024
Inventiva (TG:6IV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Inventiva (TG:6IV)
Historical Stock Chart
From Dec 2023 to Dec 2024